Roivant Posts Unexpected Q4 Profit of $355.7M Driven by $770M Moderna Settlement
ROIV has more than doubled off its 52-week low of $10.58.
Summary
Roivant Sciences reported an unexpected Q4 net profit of $355.7 million, significantly beating analyst expectations for income from operations. This positive swing was primarily driven by a substantial $770 million gain from a litigation settlement with Moderna. While the company's previous 10-Q mentioned positive legal updates, the specific financial impact and the resulting unexpected profit were not disclosed, making this new and material information. This one-time gain provides a significant boost to the company's financials and demonstrates a successful resolution to a legal dispute. Looking ahead, Roivant anticipates launching brepocitinib in dermatomyositis by late September 2026 and expects topline Phase 3 data for brepocitinib in non-infectious uveitis and Phase 2 data for mosliciguat in PH-ILD in the second half of 2026, which are key catalysts for future growth.
At the time of this announcement, ROIV was trading at $28.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $10.58 to $30.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.